Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

Inclusion Criteria: * Have signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form prior to any study-specific evaluation * Be ≥18 yrs of age at the time the informed consent form is signed * Be either AR-directed therapy-naive or have received 1-2 lines of AR-directed therapy in the castration-resistant setting. * Adequate organ function * ECOG 0 or 1 * Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate that is metastatic * Be surgically or medically castrated, with serum testosterone levels of ≤ 50 ng/dL (1.73 nM) * Have disease progression after initiation of most recent therapy Exclusion Criteria: * Active second malignancy, with the exception of curatively treated non melanoma skin cancer, carcinoma in situ, or superficial bladder cancer * Have received greater than 2 previous lines of chemotherapy for mCRPC * Prior treatment with any PARP inhibitor * Symptomatic and/or untreated central nervous system metastases * Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of study drug * Spinal cord compression, symptomatic and/or untreated central nervous system (CNS) metastases or leptomeningeal disease. Patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks * Any clinically significant cardiovascular disease * Taking any concomitant medications or herbs that could interfere or interact with the study drug